Executive Summary
According to Azoth Analytics research report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.
The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.
Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.
Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient's symptoms, the stage of the disease, and a patient's overall health.
Scope of the Report
- The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.
- The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
- The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).
- The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).
- The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).
- The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
- The attractiveness of the market has been presented by region, by Drug Class and by End User.
- Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
- The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.
Key Target Audience
- Pharmaceutical and Healthcare Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Idiopathic Pulmonary Fibrosis Market: Product Outlook
4. Global Idiopathic Pulmonary Fibrosis Market: Sizing and Forecast
4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
5. Global Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User
5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type
5.1.1 Nintedanib - Market Size and Forecast (2016-2026)
5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)
5.1.3 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User
5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)
5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)
5.2.3 Others - Market Size and Forecast (2016-2026)
6. Global Idiopathic Pulmonary Fibrosis Market: Regional Analysis
6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region
7. North America Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies
7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis
7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country
7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8. Europe Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis
8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country
8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9. Asia Pacific Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country
9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
10. Global Idiopathic Pulmonary Fibrosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026
11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026
11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 AbbVie Inc.
13.2 Bristol-Myers Squibb
13.3 F. Hoffman-La Roche Ltd.
13.4 Boehringer Ingelheim
13.5 Merck KGaA
13.6 Gilead Sciences
13.7 Liminal Biosciences
13.8 Cipla
13.9 Galapagos NV
13.10 FibroGen
13.11 Medicinova Inc.
List of Figures
Figure 1: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: GDP per Capita Growth (annual %), 2015-2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global IPF - Number of Drugs by Phase
Figure 8: Global Idiopathic Pulmonary Fibrosis Market- By Drug Type Market Share, 2020 & 2026
Figure 9: Global Idiopathic Pulmonary Fibrosis Market- By Nintedanib, By Value (USD Million), 2016-2026
Figure 10: Global Idiopathic Pulmonary Fibrosis Market- By Pirfenidone, By Value (USD Million), 2016-2026
Figure 11: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Idiopathic Pulmonary Fibrosis Market- By End User Market Share, 2020 & 2026
Figure 13: Global Idiopathic Pulmonary Fibrosis Market- By Hospitals and Clinics, By Value (USD Million), 2016-2026
Figure 14: Global Idiopathic Pulmonary Fibrosis Market- By Academics and Research Organization, By Value (USD Million), 2016-2026
Figure 15: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
Figure 16: Global Idiopathic Pulmonary Fibrosis Market- By Region Market Share, 2020 & 2026
Figure 17: North America Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 18: North America Current health expenditure(% of GDP)2014-2018
Figure 19: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 20: North America Population ages 65 and above (% of total Population), 2016-2020
Figure 21: North America Idiopathic Pulmonary Fibrosis company market share (%), 2020
Figure 22: North America Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 23: North America Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 24: Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
Figure 25: North America Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 26: United States Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 27: United States Distribution of Diagnosed IPF Patients, 2020
Figure 28: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 29: United States Population aged 65 and above (% of total Population), 2016-2020
Figure 30: United States Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 31: United States Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 32: Canada Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: Canada Population aged 65 and above (% of total Population), 2016-2020
Figure 36: Canada Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 37: Canada Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 38: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Europe Distribution of Diagnosed IPF Patients, 2020
Figure 40: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 41: European Countries Population ages 65 and above (% of total Population), 2020
Figure 42: Europe Idiopathic Pulmonary Fibrosis company market share (%), 2020
Figure 43: Europe Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 44: Europe Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 45: Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
Figure 46: Europe Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 47: Germany Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 48: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 49: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 50: Germany Urban population growth,(Annual %) 2015-2020 (In %)
Figure 51: Germany Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 52: Germany Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 53: United Kingdom Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 54: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 55: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 56: United Kingdom Population ages 65 and above (% of total Population), 2016-20
Figure 57: United Kingdom Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 58: United Kingdom Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 59: France Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 61: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 62: France Population ages 65 and above (% of total Population), 2016-20
Figure 63: France Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 64: France Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 65: Italy Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 66: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 67: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 68: Italy Population ages 65 and above (% of total Population), 2016-20
Figure 69: Italy Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 70: Italy Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 71: Spain Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 72: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 73: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 74: Spain Urban population Growth (Annual %), 2016-2020 (In %)
Figure 75: Spain Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 76: Spain Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 77: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 78: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 79: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 80: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 81: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 82: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 83: Market Opportunity Chart of APAC Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year-2026)
Figure 84: APAC Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 85: China Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 86: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 87: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 88: China Population ages 65 and above (% of total Population), 2016-20
Figure 89: China Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 91: Japan Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 92: Japan Europe Distribution of Diagnosed IPF Patients, 2020
Figure 93: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 94: Japan Population ages 65 and above (% of total Population), 2016-20
Figure 95: Japan Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 96: Japan Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 97: India Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 99: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 100: India Population ages 65 and above (% of total Population), 2016-20
Figure 101: India Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 102: India Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 103: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Drug Type (Year-2016-2026)
Figure 104: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By End User (Year 2016-2026)
Figure 105: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Region (Year 2016-2026)
Figure 106: Global Idiopathic Pulmonary Fibrosis company market share
Figure 107: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 108: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 109: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 110: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 111: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 112: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 113: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 114: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 115: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 116: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 117: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 118: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 119: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Figure 120: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Figure 121: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Figure 122: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
Figure 123: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 124: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 125: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 126: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 127: Gilead Sciences, Revenue, 2016-2020 (USD Million)
Figure 128: Gilead Sciences, Net Income 2016-2020 (USD Million)
Figure 129: Gilead Sciences, Revenue, By Business Segment (%), FY2020
Figure 130: Gilead Sciences Revenue, By Geographical Segment (%), FY2020
Figure 131: Liminal Biosciences, Revenue, 2016-2020 (USD Million)
Figure 132: Liminal Biosciences, Net Loss 2016-2020 (USD Million)
Figure 133: Liminal Biosciences, Revenue, By Business Segment (%), FY2020
Figure 134: Liminal Biosciences Revenue, By Geographical Segment (%), FY2020
Figure 135: Cipla Sales Revenues, 2016-2020 (USD Million)
Figure 136: Cipla sales Revenues, By Business Segment (%), FY2020
Figure 137: Cipla sales Revenue, By Geographical Segment (%), FY2020
Figure 138: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020
Figure 139: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020
Figure 140: FibroGen, Revenue, 2016-2020 (USD Million)
Figure 141: FibroGen, Net Loss 2016-2020 (USD Million)
Figure 142: MediciNova, Inc., Total Operating Expenses, 2015-2019 (USD Million)
Figure 143: MediciNova Inc., Net Loss 2015-2019 (USD Million)
List of Tables
Table A Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table B Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table C Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table D Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies - Vicore Pharma
Table E Deals in IPF and severe cough
Global Idiopathic Pulmonary Fibrosis Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 83
The global Idiopathic Pulmonary Fibrosis Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is es......
Idiopathic Pulmonary Fibrosis Drug - Global Market Insights and Sales Trends 2024
Published: 21-Dec-2023 Price: US 3350 Onwards Pages: 93
The global Idiopathic Pulmonary Fibrosis Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Idiopathic Pulmonary Fibrosis Drug in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Idiopathic Pulmonary Fibrosis Drug market. Glucocorticoid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ milli......
Global Idiopathic Pulmonary Fibrosis Drug Market Research Report 2023, Forecast to 2028
Published: 19-Dec-2023 Price: US 2680 Onwards Pages: 159
Idiopathic pulmonary fibrosis (IPF) is scarring or thickening of the lungs without a known cause.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital......
Global Idiopathic Pulmonary Fibrosis Drug Professional Survey Report 2023, Forecast to 2028
Published: 19-Dec-2023 Price: US 3280 Onwards Pages: 106
Idiopathic pulmonary fibrosis (IPF) is scarring or thickening of the lungs without a known cause.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital......
Global Idiopathic Pulmonary Fibrosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 16-Nov-2023 Price: US 3380 Onwards Pages: 109
Market Overview of Global Idiopathic Pulmonary Fibrosis Drug market:
According to our latest research, the global Idiopathic Pulmonary Fibrosis Drug market looks promising in the next 5 years. As of 2022, the global Idiopathic Pulmonary Fibrosis Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and compre......
Global Pirfenidone Market Research Report 2023, Forecast to 2028
Published: 13-Nov-2023 Price: US 2680 Onwards Pages: 166
Pirfenidone is used for the treatment of idiopathic pulmonary fibrosis (scarring of the lungs with an unknown cause).
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches......
Global Pirfenidone Professional Survey Report 2023, Forecast to 2028
Published: 13-Nov-2023 Price: US 3280 Onwards Pages: 109
Pirfenidone is used for the treatment of idiopathic pulmonary fibrosis (scarring of the lungs with an unknown cause).
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches......
Global Pirfenidone Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 03-Oct-2023 Price: US 3380 Onwards Pages: 121
Market Overview of Global Pirfenidone market:
According to our latest research, the global Pirfenidone market looks promising in the next 5 years. As of 2022, the global Pirfenidone market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Pirfenidone market, with a systematica......
Global Idiopathic Pulmonary Fibrosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Sep-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Idiopathic Pulmonary Fibrosis market:
According to our latest research, the global Idiopathic Pulmonary Fibrosis market looks promising in the next 5 years. As of 2022, the global Idiopathic Pulmonary Fibrosis market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysi......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
